CDTTW News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CD

Volume

210.46K

Loading chart

CD

CDTTWCDT Equity Inc. Warrant

CDTTW

Pay with—

Available Balance0.00

CD

Mkt Cap

N/A

Volume

210.46K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

CDT Provides Capital Update and Confirms No Nasdaq DeficienciesCDT Equity Inc. (Nasdaq: CDT) announced 13.7 million shares outstanding as of August 31, 2026, with a market capitalization of approximately $23.0 million. The company confirmed it no longer has outstanding deficiencies with Nasdaq following recent share issuances and corporate actions. CDT, a data-driven biopharmaceutical development company, reported stockholders' equity of approximately $103 million as of June 30, 2026.GlobeNewswire Inc. · Sep 2, 2026

CDT Validates Enhanced Solid-Form Properties Within Its IP PortfolioCDT Equity Inc. announced the development of new solid forms and crystal structures of its existing drug compounds with improved stability, solubility, and manufacturability. The company has filed patents for new therapeutic uses identified through AI-driven analysis, targeting underserved patient populations. CDT plans to advance these findings through laboratory models and pursue licensing partnerships, aiming to create a differentiated, patent-protected portfolio with reduced scientific risk.GlobeNewswire Inc. · Aug 28, 2026

CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide MarketCDT Equity Inc. (Nasdaq: CDT) announced a SAFE note investment in Pep'd Inc., a US-based peptide telehealth company, to gain exposure to the growing peptide therapeutics market projected to reach $294.6 billion by 2033. The investment leverages AI-enabled approaches for peptide development and combines telehealth with research capabilities. Pep'd is controlled by CDT's CEO Dr. Andrew Regan.GlobeNewswire Inc. · Aug 25, 2026

What's Going On With CDT Equity Shares On Monday?CDT Equity (NASDAQ:CDT) shares rose 14.71% to $4.68 on Monday despite the health care sector declining 2.63% over the past 30 days. The rally comes after the biopharmaceutical company disclosed a widened net loss of $39.1 million for 2025 and filed a non-timely 10K. Technical analysis shows the stock trading 49.1% below its 20-day moving average and 84.6% below its 100-day moving average, with the stock down 99.83% over the past 12 months. The company is set to report earnings on April 24.Benzinga · Apr 13, 2026

CDT Positions for Transformational GrowthCDT Equity Inc. (NASDAQ:CDT) announced multiple strategic initiatives to enhance shareholder value, including its 20% equity stake acquisition in Sarborg AI for $115 million, continued development of its pharmaceutical portfolio with AstraZeneca-licensed assets, and evaluation of capital markets initiatives to strengthen financial flexibility.Benzinga · Mar 4, 2026

to start trading

CD

CDTTWCDT Equity Inc. Warrant

CDTTW

Pay with—

Available Balance0.00

Your PositionYou don't own any CDTTW yet.

Related Tickers

Earnings